Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News bluebird bio Inc. BLUEV


Primary Symbol: BLUE

bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.


Recent & Breaking News (NDAQ:BLUE)

FINAL DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA April 2, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of bluebird bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 13, 2021 - BLUE

Newsfile April 2, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in bluebird bio, Inc. of Class Action Lawsuit and Upcoming Deadline - BLUE

ACCESSWIRE IA April 1, 2021

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages bluebird bio, Inc. Investors to Secure Counsel Before Important April 13 Deadline in Securities Class Action - BLUE

ACCESSWIRE IA April 1, 2021

FINAL DEADLINE THIS MONTH: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA April 1, 2021

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against bluebird bio, EHang, fuboTV and Jianpu Technology Encourages Investors to Contact the Firm

GlobeNewswire March 31, 2021

BLUE DEADLINE ALERT: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against  bluebird bio, Inc. - BLUE

GlobeNewswire March 31, 2021

DEADLINE ALERT for BLUE, EH, JT, IMVT: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

GlobeNewswire March 30, 2021

CLOV, BLUE & EH Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Shareholders to Contact the Firm

ACCESSWIRE IA March 30, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in bluebird bio, Inc. of Class Action Lawsuit and Upcoming Deadline - BLUE

Newsfile March 29, 2021

BLUE CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc.

GlobeNewswire March 29, 2021

DEADLINE ALERT for BLUE, EH, and JT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

GlobeNewswire March 29, 2021

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages bluebird bio, Inc. Investors to Secure Counsel Before Important April 13 Deadline in Securities Class Action - BLUE

GlobeNewswire March 28, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in bluebird bio, Inc. of Class Action Lawsuit and Upcoming Deadline - BLUE

ACCESSWIRE IA March 27, 2021

U.S. Food and Drug Administration Approves Bristol Myers Squibb's and bluebird bio's Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma

Business Wire March 26, 2021

ROSEN, A LEADING LAW FIRM, Encourages bluebird bio, Inc. Investors with LARGE LOSSES to Secure Counsel Before Important April 13 Deadline in Securities Class Action - BLUE

ACCESSWIRE IA March 26, 2021

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)

GlobeNewswire March 26, 2021

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA March 26, 2021

FINAL DEADLINE APPROACHING: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA March 25, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of bluebird bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 13, 2021 - BLUE

Newsfile March 24, 2021